American Association for Cancer Research
Browse

Contents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming

Download (13.01 kB)
journal contribution
posted on 2025-02-21, 18:20 authored by Ilaria Gritti, Jinkai Wan, Vajira Weeresekara, Joel M. Vaz, Giuseppe Tarantino, Tenna Holgersen Bryde, Vindhya Vijay, Ashwin V. Kammula, Prabhat Kattel, Songli Zhu, Phuong Vu, Marina Chan, Meng-Ju Wu, John D. Gordan, Krushna C. Patra, Vanessa S. Silveira, Robert T. Manguso, Marc N. Wein, Christopher J. Ott, Jun Qi, David Liu, Kei Sakamoto, Taranjit S. Gujral, Nabeel Bardeesy

List of contents of each Supplementary Table

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Alex’s Lemonade Stand Foundation for Childhood Cancer (ALSF)

Fibrolamellar Cancer Foundation (FCF)

Bertarelli Rare Cancers Fund

Novo Nordisk Fonden (NNF)

American-Italian Cancer Foundation (AICF)

History

ARTICLE ABSTRACT

This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the SIK stimulates CRTC2-p300-mediated transcription to drive tumor growth. The findings illuminate pathogenic mechanisms and inform therapeutic development.